
TRAPnSeq allows high-throughput profiling of antigen-specific antibody-secreting cells dlvr.it/SrrW3Y

Antibodies, Immunology, Protein Engineering, Comp Bio. @urichmond, @VanderbiltU and @Regeneron alum. Views mine.

TRAPnSeq allows high-throughput profiling of antigen-specific antibody-secreting cells dlvr.it/SrrW3Y

High-throughput discovery of #epitope-specific #antibodies? There's a #LIBRAseq for that. Great collaborative effort led by @LaurenW_Science. High-Throughput B Cell Epitope Determination by Next-Generation Sequencing frontiersin.org/article/10.3…

#LIBRAseq with ligand blocking enables targeted discovery of functional (not just binding) #antibodies. Double #ACE2-blockers for both #SARSCoV2 and #SARSCoV were also identified. Easily generalizable for #mAb discovery aiming to block other types of antigen-ligand interactions
Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking go.nature.com/35O9Ali

Great place to do science!
We have a postdoctoral opening in antibody discovery, with a special emphasis on the development and application of innovative #bioinformatics technologies. Come do cutting-edge research in #antibody and #vaccine science in #Nashville, one of the hottest destinations in the US!

Congrats @IG_lab @kjkramer6 @AShiakolas and all
Out now in @CellReports: Potent neutralization of #SARSCoV2 variants of concern (including #Delta) by an #antibody with an uncommon genetic signature and structural mode of spike recognition cell.com/cell-reports/fullte…

Out now in @CellReports: Potent neutralization of #SARSCoV2 variants of concern (including #Delta) by an #antibody with an uncommon genetic signature and structural mode of spike recognition cell.com/cell-reports/fullte…


Announcing our Phase 3 trial in advanced #CervicalCancer was stopped early after achieving its primary efficacy endpoint. Today’s milestone is a “first” for the cervical cancer community. Learn why: https://t.co/ePL40tmYfR CC: @Sanofi


We're looking for a computational immunologist. Come join us! careers.regeneron.com/6gQLWZ…


With @Sanofi, we are announcing the FDA approval of our #immunotherapy in first-line advanced #NonSmallCellLungCancer (#NSCLC) with ≥50% PD-L1 expression. Learn more: https://t.co/A5PzpTqoz0


Announcing with @Sanofi, the FDA has granted full approval to our #immunotherapy for patients with locally advanced #BasalCell Carcinoma (#BCC) and accelerated approval for patients with metastatic #BCC. Learn more: https://t.co/Zu8cicfaad

Great place to do science!
Pursue your passion for #science in a dynamic and innovative environment. Apply by December 1 to be a part of the Regeneron Postdoctoral Program.

The FDA has issued an Emergency Use Authorization for our investigational antibody cocktail to treat mild to moderate #COVID19 in certain high-risk patients 12 years and older. Learn more: https://t.co/yNfOFPyLI0